# NCT03909334 (NCT03909334)

> Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03909334
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Xiuning Le
- Conditions: Non Small Cell Lung Cancer; EGFR Gene Mutation; Advanced Cancer; Metastatic Cancer
- Interventions: Osimertinib; Ramucirumab
- Enrollment: 160
- Primary outcome: Progression Free Survival (PFS)

## Indexed commentary on NCT03909334 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 5 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct03909334